Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03615196 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety of USB005 in Healthy Volunteers
A Phase 1 study, sponsored by US Biotest.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT03615196 is a Phase 1 study that has completed, run by US Biotest. The registered enrollment target is 32 participants.
The verdict
NCT03615196, a Phase 1 study, has completed, sponsored by US Biotest.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.
Interventions
- DRUG USB005 (aclerastide) Ophthalmic Solution
- DRUG USB005 Ophthalmic Solution Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-07-25 |
| Est. Completion | 2019-04-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03615196
The ClinicalTrials.gov registry entry for NCT03615196 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is US Biotest, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which USB005 (aclerastide) Ophthalmic Solution is the first listed.
NCT03615196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03615196 about?
NCT03615196 is a clinical study titled "Study of the Safety of USB005 in Healthy Volunteers". This study will evaluate the safety, tolerability and pharmacokinetics of USB005 (aclerastide) Ophthalmic Solution.
What is the current status of trial NCT03615196?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2018-07-25. Estimated completion is 2019-04-02.
What interventions are being tested in trial NCT03615196?
The interventions under investigation include: USB005 (aclerastide) Ophthalmic Solution (DRUG), USB005 Ophthalmic Solution Placebo (DRUG).
Who is sponsoring clinical trial NCT03615196?
This trial is sponsored by US Biotest, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.